Cholangiocarcinoma 2020: the next horizon in mechanisms and management
JM Banales, JJG Marin, A Lamarca… - Nature reviews …, 2020 - nature.com
Cholangiocarcinoma (CCA) includes a cluster of highly heterogeneous biliary malignant
tumours that can arise at any point of the biliary tree. Their incidence is increasing globally …
tumours that can arise at any point of the biliary tree. Their incidence is increasing globally …
Cholangiocarcinoma
PJ Brindley, M Bachini, SI Ilyas, SA Khan… - Nature reviews Disease …, 2021 - nature.com
Cholangiocarcinoma (CCA) is a highly lethal adenocarcinoma of the hepatobiliary system,
which can be classified as intrahepatic, perihilar and distal. Each anatomic subtype has …
which can be classified as intrahepatic, perihilar and distal. Each anatomic subtype has …
Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians
Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver tumor and
remains a fatal malignancy in the majority of patients. Approximately 20%–30% of patients …
remains a fatal malignancy in the majority of patients. Approximately 20%–30% of patients …
Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆
Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆ -
Annals of Oncology Skip to Main Content Advertisement Annals of Oncology European Society …
Annals of Oncology Skip to Main Content Advertisement Annals of Oncology European Society …
Gallbladder cancer
Gallbladder cancer (GBC) is the most common cancer of the biliary tract, characterized by a
very poor prognosis when diagnosed at advanced stages owing to its aggressive behaviour …
very poor prognosis when diagnosed at advanced stages owing to its aggressive behaviour …
Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus …
Background The prognosis of patients with advanced biliary tract cancer who have
progressed on gemcitabine plus cisplatin is dismal. We aimed to investigate the efficacy and …
progressed on gemcitabine plus cisplatin is dismal. We aimed to investigate the efficacy and …
Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial
K Nakachi, M Ikeda, M Konishi, S Nomura, H Katayama… - The Lancet, 2023 - thelancet.com
Background S-1 has shown promising efficacy with a mild toxicity profile in patients with
advanced biliary tract cancer. The aim of this study was to evaluate whether adjuvant S-1 …
advanced biliary tract cancer. The aim of this study was to evaluate whether adjuvant S-1 …
Systemic therapies for intrahepatic cholangiocarcinoma
RK Kelley, J Bridgewater, GJ Gores, AX Zhu - Journal of hepatology, 2020 - Elsevier
Intrahepatic cholangiocarcinoma (iCCA) is a highly lethal hepatobiliary neoplasm whose
incidence is increasing. Largely neglected for decades as a rare malignancy and frequently …
incidence is increasing. Largely neglected for decades as a rare malignancy and frequently …
Biliary tract cancer
JW Valle, RK Kelley, B Nervi, DY Oh, AX Zhu - The Lancet, 2021 - thelancet.com
Biliary tract cancers, including intrahepatic, perihilar, and distal cholangiocarcinoma as well
as gallbladder cancer, are low-incidence malignancies in most high-income countries, but …
as gallbladder cancer, are low-incidence malignancies in most high-income countries, but …
Molecular targeted therapies: ready for “prime time” in biliary tract cancer
A Lamarca, J Barriuso, MG McNamara, JW Valle - Journal of hepatology, 2020 - Elsevier
The prognosis for patients with biliary tract cancers (cholangiocarcinoma and gallbladder
cancer) is poor, while the incidence of these cancers is increasing. Most patients are …
cancer) is poor, while the incidence of these cancers is increasing. Most patients are …